Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis

Federica Azzolini1, Luana Gilio1, Luigi Pavone1

  • 1IRCCS Neuromed, 86077 Pozzilli, Italy.

Biomolecules
|February 25, 2022
PubMed

Insights

Glial fibrillary acid protein (GFAP) and soluble triggering receptors expressed on myeloid cells-2 (sTREM-2) in cerebrospinal fluid (CSF) correlate with inflammation and clinical features in relapsing-remitting multiple sclerosis (RRMS). Elevated GFAP may indicate higher progression risk.

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Multiple Sclerosis Pathogenesis

Background:

  • Astrocytes and microglia are key players in multiple sclerosis (MS) neuroinflammation.
  • Investigating glial markers like GFAP and sTREM-2 in CSF offers insights into MS inflammatory processes.

Purpose of the Study:

  • To explore the relationship between CSF GFAP and sTREM-2 levels with inflammatory molecules and clinical/MRI characteristics in relapsing-remitting MS (RRMS).
  • To identify potential biomarkers for MS inflammation and progression risk.

Main Methods:

  • Analysis of CSF from 51 RRMS patients at diagnosis.
  • Quantification of GFAP, sTREM-2, and various inflammatory/anti-inflammatory molecules in CSF.
  • Assessment of MRI structural measures including cortical thickness, T2 lesion load, and cerebellar volume.

Main Results:

  • CSF GFAP and sTREM-2 levels correlated significantly with inflammatory cytokines (IL-8, G-CSF, IL-5) and positively with age at diagnosis.
  • Higher GFAP levels were observed in male MS patients and associated with increased MS progression risk (higher BREMS).
  • A negative association was found between CSF GFAP levels and cerebellar volume in RRMS patients at diagnosis.

Conclusions:

  • GFAP and sTREM-2 are validated biomarkers for central nervous system inflammation in MS.
  • Elevated CSF GFAP levels in RRMS patients may predict a higher risk of disease progression.